神経内分泌腫瘍治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Neuroendocrine Tumors - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0640
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:692
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Neuroendocrine Tumors – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors – Pipeline Review, H2 2019, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape.

Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Neuroendocrine Tumors – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 29, 31, 2, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Neuroendocrine Tumors (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors (Oncology).
- The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuroendocrine Tumors (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuroendocrine Tumors (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuroendocrine Tumors (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuroendocrine Tumors (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Neuroendocrine Tumors – Overview
Neuroendocrine Tumors – Therapeutics Development
Neuroendocrine Tumors – Therapeutics Assessment
Neuroendocrine Tumors – Companies Involved in Therapeutics Development
Neuroendocrine Tumors – Drug Profiles
Neuroendocrine Tumors – Dormant Projects
Neuroendocrine Tumors – Discontinued Products
Neuroendocrine Tumors – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Neuroendocrine Tumors, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Neuroendocrine Tumors - Pipeline by Aadi Bioscience Inc, H2 2019
Neuroendocrine Tumors - Pipeline by Advanced Accelerator Applications SA, H2 2019

【掲載企業】

Aadi Bioscience Inc
Advanced Accelerator Applications SA
Akeso Biopharma Inc
AnHeart Therapeutics Inc
Aquestive Therapeutics Inc
Ascil Proyectos SL
Beijing Foreland Pharma Co Ltd
Bioncotech Therapeutics SL
Boehringer Ingelheim International GmbH
BriaCell Therapeutics Corp
Bristol-Myers Squibb Co
Camurus AB
CanBas Co Ltd
Clarity Pharmaceuticals Pty Ltd
Crinetics Pharmaceuticals Inc
Dauntless Pharmaceuticals Inc
DexTech Medical AB
Eli Lilly and Co
Enterome Bioscience SA
EpicentRx Inc
Esanex Inc
Esperance Pharmaceuticals Inc
Exelixis Inc
Foresee Pharmaceuticals Co Ltd
GEMoaB Monoclonals GmbH
HEC Pharm Co Ltd
Hutchison MediPharma Ltd
Innovent Biologics Inc
INVENT Pharmaceuticals Inc
Ipsen SA
Jubilant DraxImage Inc
Karyopharm Therapeutics Inc
Lexicon Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
Mateon Therapeutics Inc
Merck & Co Inc
Merck KGaA
Midatech Pharma Plc
Millennium Pharmaceuticals Inc
MimiVax LLC
Mina Therapeutics Ltd
Molecular Targeting Technologies Inc
Molecular Templates Inc
Nanovalent Pharmaceuticals Inc
Northwest Biotherapeutics Inc
Novartis AG
Oncoceutics Inc
Oncology Venture U.S. Inc
Ono Pharmaceutical Co Ltd
Orano Med LLC
Pfizer Inc
Pharma Mar SA
Progenics Pharmaceuticals Inc
ProLynx LLC
Provectus Biopharmaceuticals Inc
Regulaxis SAS
Rhizen Pharmaceuticals SA
Seneca Therapeutics Inc
Shanghai Junshi Bioscience Co Ltd
Sichuan Huiyang Life Science and Technology Corp
Strongbridge Biopharma plc
Suntec Medical (Taiwan) Inc
Taiho Pharmaceutical Co Ltd
Tarveda Therapeutics Inc
Teclison Ltd
Trio Medicines Ltd
Vanquish Oncology Inc
Veana Therapeutics LLC
Xencor Inc


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[神経内分泌腫瘍治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆